EXPERT OPINION ON THERAPEUTIC PATENTS

简称 EXPERT OPIN THER PAT ·ENGLAND ·出版周期 Monthly ·年均收录 109 篇

4.6

最新影响因子

4.40%

自引率

一般

投稿难度

较慢,6-12周

审稿周期

期刊简介

EXPERT OPINION ON THERAPEUTIC PATENTS是一本专注于治疗专利领域的国际期刊，ISSN号为1354-3776，由英国出版商TAYLOR & FRANCIS LTD出版，出版地为英国，出版周期为月刊。该期刊的影响因子较高，具体数值需查阅最新JCR报告，属于SCI收录期刊，中科院分区情况需根据年度分区表确认，目前为非开放获取（非OA）期刊。杂志的发文特点集中于药物研发、专利分析、治疗技术创新等领域，尤其关注专利药物的临床前和临床研究进展，为行业提供权威的专家观点和前沿动态。其质量较高，文章多由领域内知名专家撰写，但作为专利相关期刊，可能存在一定的商业利益关联风险，读者需结合自身需求谨慎参考。总体而言，该期刊在药物专利与治疗技术领域具有较高的学术价值和行业影响力。

影响因子趋势

近期发表

Global patent landscape of synthetic drugs for melasma (2015–2025): innovation trends, mechanistic shifts, and translational challenges 2026-09-11

Aurora kinase inhibitors: an updated patent review (2021–present) 2026-09-14

Overcoming the blood–brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020–present) 2026-08-27

Selective PARP1 inhibitors (2021–2025): patent landscape, structural evolution, and future therapeutic opportunities 2026-08-19

An updated patent review of STAT6 inhibitors and modulators (2020 – present) 2026-08-06

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure–activity relationships and patent coverage 2026-07-27

T-type calcium channel blockers: a review of recent advances (2018–2025) 2026-08-01

Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present) 2026-07-27

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025) 2026-07-28

A patent perspective of RSK inhibitors to treat cancer (2020-present) 2026-07-27